Abstract
To report prostate cancer outcomes, toxicity, and quality of life (QOL) in men treated with proton beam therapy (PBT). Patients were enrolled in a prospective trial. All participants received 75.6 to 78 Gy (RBE). Up to 6 months of luteinizing hormone-releasing hormone agonist therapy was allowed. The Phoenix definition defined biochemical failure. Modified Radiation Therapy Oncology Group criteria defined toxicity. Expanded Prostate Cancer Index Composite questionnaires objectified QOL. Clinically significant QOL decrement was defined as ≥0.5 × baseline standard deviation. In total, 423 men were analyzed. The National Comprehensive Cancer Network risk classification was used (low 43%; intermediate 56%; high 1%). At the 5.2-year median follow-up, overall and disease-specific survival rates were 99.8% and 100%, respectively. Cumulative biochemical failure rate was 5.2% (95% confidence interval [CI] = 3.0%-8.3%); acute grade 2 genitourinary (GU) toxicity was 46.3%; acute grade 2 gastrointestinal (GI) toxicity was 5.0% (95% CI = 3.1%-7.3%). There was no acute grade ≥3 GI or GU toxicity. Cumulative late grade 2 GU and GI toxicity was 15.9% (95% CI = 13%-20%) and 9.7% (95% CI = 6.5%-12%), respectively. There were 2 grade 3 late GI toxicities (rectal bleeding) and no late grade ≥3 GU toxicity. The 4-year mean Expanded Prostate Cancer Index Composite urinary, bowel, sexual, and hormonal summary scores (range; standard deviation) were 89.7 (43.8-100; 11), 91.3 (41.1-94.6; 10), 57.8 (0.0-96.2; 27.1), and 92.2 (25-95.5; 10.5), respectively. Compared with baseline, there was no clinically significant decrement in urinary, sexual, or hormonal QOL after treatment completion. A modest (<10 points), yet clinically significant, decrement in bowel QOL was appreciated throughout follow-up. Contemporary PBT resulted in excellent biochemical control, minimal risk of higher-grade toxicity, and modest QOL decrement. Further investigation comparing PBT with alternative prostate cancer treatment strategies are warranted.
Highlights
Proton beam therapy (PBT) has been used as curative intent prostate cancer treatment for more than 40 years [1], the application of this technology has been relatively limited due to the paucity of proton therapy centers
To assess which quality of life (QOL) domains were affected, we evaluated the time profiles of EPIC-50 scores to assess whether the mean score changes from baseline at each follow-up time point were different using a one-sample t test
Modified Radiation Therapy Oncology Group toxicity by grade in men treated with proton beam therapy for localized prostate cancer
Summary
Proton beam therapy (PBT) has been used as curative intent prostate cancer treatment for more than 40 years [1], the application of this technology has been relatively limited due to the paucity of proton therapy centers. Distinct physical properties afford PBT radiation dose deposition advantages to nontarget anatomy while facilitating dose escalation to intended treatment targets compared with alternative forms of external beam radiation [2, 3]. Institutional protocol 2005-0956 is a single-arm prospective registry trial designed to estimate survival, cancer control, toxicity, and patient-reported quality of life (QOL) in men receiving contemporary dose-escalated PBT for localized prostate cancer. Results from this trial are presented here
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
